ArticleNPJ precision oncology2024

Exploiting tumor aneuploidy as a biomarker and therapeutic target in patients treated with immune checkpoint blockade.

Liam F Spurr et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.